Long R3 IGF-1 vs IGF-1 LR3 — Same Peptide Explained

Long R3 IGF-1 vs IGF-1 LR3 — Same Peptide Explained Long R3 IGF-1 and IGF-1 LR3 are identical research peptides with the same modified amino acid sequence and extended half-life for lab studies. Research labs ordering peptides for the first time often waste hours verifying whether Long R3 IGF-1 and IGF-1 LR3 are different compounds. They're not. Both names refer to the same synthetic analog of insulin-like growth factor-1 (IGF-1), modified at the N-terminus with a 13-amino-acid extension and an arginine substitution at position 3. The confusion stems from inconsistent vendor nomenclature. Some suppliers list it as 'Long R3', others as 'LR3', and a few write out 'Long Arg3'. But the molecular structure, CAS number (946870-92-4), and biological function remain identical across all three naming conventions. Our team supplies research-grade peptides to biological research institutions, and we've clarified this naming ambiguity hundreds of times. The functional distinction that matters isn't the name. It's understanding why this analog exists in the first place and how its structural modifications differ from endogenous IGF-1. Is Long R3 IGF-1 the same compound as IGF-1 LR3? Yes. Long R3 IGF-1 and IGF-1 LR3 are identical peptides. Both names describe the same 83-amino-acid synthetic analog of human IGF-1, featuring a 13-residue N-terminal extension and an arginine substitution at position 3 (replacing glutamic acid). This modification reduces binding affinity to IGF binding proteins (IGFBPs) by approximately 100-fold compared to native IGF-1, extending the peptide's functional half-life in vitro from minutes to hours. Research applications rely on this extended bioavailability to study IGF-1 receptor signaling pathways without the rapid clearance seen with unmodified IGF-1. The naming convention split happened during early commercial synthesis in the 1990s. Academic publications typically used 'Long R3 IGF-1' to describe the structural modification (long N-terminal extension, arginine at position 3). Suppliers shortened this to 'LR3' for catalog listings, and both stuck. You'll see 'Long R3 IGF-1' in peer-reviewed studies published in journals like Endocrinology and The Journal of Biological Chemistry, while commercial peptide vendors. Including Real Peptides. Commonly use 'IGF-1 LR3' for product identification. The peptide synthesis protocol, purity standards, and amino acid sequencing remain identical regardless of which abbreviation appears on the vial label. Native human IGF-1 has a functional half-life measured in minutes when introduced to cell culture or in vivo models. The reason: IGF binding proteins (IGFBPs 1–6) sequester free IGF-1 almost immediately after it enters circulation or culture media, preventing receptor engagement. For researchers studying IGF-1 receptor (IGF-1R) activation, this creates a logistical problem. Maintaining consistent signaling requires constant peptide replenishment or prohibitively high concentrations to saturate binding proteins. Long R3 IGF-1 solves this by introducing two structural changes. The 13-amino-acid N-terminal extension sterically hinders IGFBP binding without affecting IGF-1R affinity. The arginine substitution at position 3 (Arg3 replacing Glu3) further reduces IGFBP-3 binding, the most abundant binding protein in serum. Together, these modifications extend functional bioavailability from under 10 minutes to 15–20 hours in standard culture conditions. A 100-fold improvement in peptide stability without requiring refrigerated media changes mid-protocol. This extended half-life matters most in multi-day protocols studying receptor desensitization, downstream signaling kinetics (PI3K/Akt and MAPK/ERK pathways), or dose-response curves where repeated media replacement would introduce confounding variables. Native IGF-1 requires dosing every 2–4 hours to maintain receptor occupancy; Long R3 IGF-1 maintains steady signaling with once-daily dosing. The same peptide appears under at least four distinct names depending on vendor, publication year, and regional supplier preferences. 'Long R3 IGF-1' is the formal descriptor used in most peer-reviewed publications and patent filings. 'IGF-1 LR3' dominates commercial catalogs and supplier websites because it's shorter and easier to parse in database searches. 'Long Arg3 IGF-1' appears occasionally in European suppliers' catalogs. 'Arg3' explicitly names the arginine substitution rather than abbreviating it to 'R3'. A fourth variant, 'LR3-IGF-I' (with a Roman numeral I instead of the number 1), shows up in older literature from the 1990s but has largely disappeared from current usage. All four refer to CAS 946870-92-4, the registry number assigned to this specific 83-amino-acid sequence. If you're cross-referencing studies or comparing supplier specs, the CAS number is the definitive identifier. It eliminates ambiguity introduced by naming convention drift. Our experience sourcing peptides for research institutions shows that verifying CAS numbers catches more labeling errors than comparing product names alone. A mislabeled vial with the correct CAS is still the right peptide; a correctly named vial with the wrong CAS is not. For procurement purposes, treat 'Long R3 IGF-1' and 'IGF-1 LR3' as interchangeable search terms. Run both through supplier databases to ensure you're seeing the full range of available products and purity grades. The peptide's functional properties. Receptor binding affinity, IGFBP resistance, half-life extension. Are determined by its amino acid sequence, not by which abbreviation appears on the product listing. Amino Acid Length 83 residues 70 residues The 13-residue N-terminal extension in Long R3 is the primary structural modification. Not a post-translational addition but a designed sequence extension Position 3 Residue Arginine (Arg) Glutamic Acid (Glu) This single substitution reduces IGFBP-3 binding affinity by 10–20-fold, critical for extended in vitro stability IGFBP Binding Affinity Reduced 100-fold vs native IGF-1 High affinity for all six IGFBPs The functional consequence: Long R3 remains bioavailable in serum-containing media where native IGF-1 would be sequestered within minutes Functional Half-Life (cell culture) 15–20 hours <10 minutes This allows once-daily dosing in multi-day protocols without media replacement. Native IGF-1 requires dosing every 2–4 hours IGF-1 Receptor Affinity Equivalent to native IGF-1 Baseline (100%) The structural modifications do not reduce receptor engagement. Signaling potency remains unchanged CAS Registry Number 946870-92-4 67763-96-6 Use CAS numbers for definitive product verification. Naming conventions vary, molecular structure does not Long R3 IGF-1 and IGF-1 LR3 are identical peptides. Both names describe the same 83-amino-acid synthetic analog with a 13-residue N-terminal extension and Arg3 substitution. The structural modifications reduce IGF binding protein affinity by approximately 100-fold, extending functional half-life from under 10 minutes to 15–20 hours in standard culture conditions. CAS number 946870-92-4 is the definitive identifier for this peptide across all naming conventions. Verify this number when cross-referencing suppliers or publications. The peptide maintains equivalent IGF-1 receptor binding affinity compared to native IGF-1 despite the structural changes, preserving downstream signaling potency through PI3K/Akt and MAPK/ERK pathways. Commercial suppliers use 'IGF-1 LR3' more frequently in product catalogs, while peer-reviewed publications typically cite 'Long R3 IGF-1'. Both refer to the same compound with identical synthesis protocols. Verify the CAS number on both product listings. If both show CAS 946870-92-4, they're the same peptide sold under two names. Potentially at different purity grades or vial sizes, but not different molecular structures. If the CAS numbers differ, contact the supplier directly for sequence verification. We've encountered cases where a supplier mistakenly listed recombinant human IGF-1 (CAS 67763-96-6) under an 'LR3' product code due to database entry errors. The CAS mismatch caught the error before shipment. A 70-amino-acid sequence indicates you received native IGF-1, not the Long R3 analog. This substitution error eliminates the extended half-life and IGFBP resistance that justify using the analog in the first place. Reject the batch and request replacement with documented proof of the 83-residue sequence. For high-stakes protocols, consider ordering a small verification sample before committing to bulk quantities. Sequence confirmation via mass spectrometry takes 3–5 business days and prevents mid-protocol failures. Proceed with the 'LR3' product if the CAS number matches. Protocol replication depends on molecular structure, not naming convention. Include a note in your methods section citing both names and the CAS number to clarify for peer reviewers that no substitution occurred. Most institutional review boards and journal editors recognize the naming equivalence, but explicit documentation prevents delays during manuscript review. Here's the honest answer: the peptide research field has no standardized naming authority for synthetic analogs, which is why identical compounds appear under multiple names across suppliers. Long R3 IGF-1 and IGF-1 LR3 are the same molecule. The naming split reflects vendor preference and historical accident, not functional difference. The confusion wastes researchers' time and procurement budgets when labs order both variants thinking they're running parallel comparisons, only to discover post-delivery that the vials contain identical peptides at identical concentrations. This isn't unique to IGF-1 analogs. The same naming fragmentation exists across growth hormone secretagogues (MK 677 listed as both 'Ibutamoren' and 'MK-677'), thymic peptides (Thymalin appearing as 'Thymulin' or 'Thymic Extract'), and neuropeptide research tools. The field lacks a centralized registry equivalent to pharmaceutical INN (International Nonproprietary Names), so suppliers create their own shorthand. Researchers working across multiple institutions or comparing historical data must cross-reference CAS numbers, not product names, to confirm peptide identity. The practical takeaway: treat 'Long R3 IGF-1' and 'IGF-1 LR3' as synonyms in procurement databases, literature searches, and protocol documentation. The peptide's functional properties. Extended bioavailability, IGFBP resistance, maintained receptor affinity. Are determined by its 83-amino-acid sequence with Arg3 substitution, not by which abbreviation appears on the label. If a supplier insists the two names represent different products, ask for the CAS numbers and amino acid sequences. If both show CAS 946870-92-4 and an 83-residue sequence starting with the 13-amino-acid extension, they're selling the same compound under two names. The confusion around Long R3 IGF-1 versus IGF-1 LR3 isn't a reflection of different peptides. It's a nomenclature artifact that persists because no regulatory body enforces naming consistency for research-grade compounds. Both names describe the same structurally modified IGF-1 analog designed to resist binding protein sequestration and maintain receptor engagement across extended protocols. For researchers sourcing peptides, the CAS number (946870-92-4) is the only identifier that eliminates ambiguity. If you're replicating a published protocol that specifies one name but your supplier uses the other, verify the CAS match and proceed. The molecular structure, not the label, determines experimental outcomes. Our team at Real Peptides synthesizes this analog under both naming conventions depending on client preference, but the synthesis protocol, purity verification, and final amino acid sequence remain identical in every batch. Yes — both names refer to the same 83-amino-acid synthetic analog of IGF-1 with a 13-residue N-terminal extension and arginine substitution at position 3. The naming difference reflects vendor convention, not molecular structure. CAS number 946870-92-4 confirms identity across all naming variations. The naming split originated in the 1990s when academic publications used ‘Long R3 IGF-1’ to describe the structural modification while commercial suppliers shortened it to ‘LR3’ for catalog listings. Both naming conventions persisted independently, creating the illusion of separate products when the peptide synthesis protocol and amino acid sequence remain identical. Check the certificate of analysis for CAS number 946870-92-4 and confirm the amino acid count is 83 residues, not 70. If both match, you received the correct analog regardless of whether the label says ‘Long R3’ or ‘LR3’. Sequence mismatches indicate you received native IGF-1 instead, which lacks the extended half-life and IGFBP resistance. Long R3 IGF-1 maintains functional bioavailability for 15–20 hours in standard cell culture conditions, compared to under 10 minutes for native IGF-1. This 100-fold extension results from reduced binding to IGF binding proteins, allowing once-daily dosing in multi-day protocols without requiring constant media replacement. Not directly — native IGF-1 requires dosing every 2–4 hours to maintain receptor occupancy because IGF binding proteins sequester free peptide within minutes. Long R3 IGF-1 resists this binding, allowing stable signaling with once-daily administration. Substituting native IGF-1 would require complete protocol redesign to account for the shorter half-life. The 13-amino-acid N-terminal extension creates steric hindrance that physically blocks IGFBP attachment sites, while the arginine substitution at position 3 specifically reduces IGFBP-3 binding affinity by 10–20-fold. Together, these modifications lower overall IGFBP binding by approximately 100-fold without reducing IGF-1 receptor affinity. It’s another naming variant for the same peptide. ‘Long Arg3 IGF-1’ explicitly states the arginine substitution at position 3 rather than abbreviating it to ‘R3’, but the molecular structure and CAS number (946870-92-4) remain identical. European suppliers use this naming convention more frequently than those based elsewhere. Yes — the structural modifications that reduce IGFBP binding do not alter IGF-1 receptor binding affinity or downstream signaling potency through PI3K/Akt and MAPK/ERK pathways. The extended bioavailability comes from reduced clearance, not from enhanced receptor engagement per molecule. Standard cell culture applications require ≥95% purity verified by HPLC, with endotoxin levels below 1 EU/mg to prevent inflammatory artifacts in cultured cells. For mechanistic studies involving receptor binding assays or kinetic measurements, ≥98% purity eliminates interference from degradation products or synthesis byproducts. Store lyop